Insiders' dealing Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR.CO) shall make public transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these. Name: Anita Milland Reason: Vice President, CFO Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 18 September 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 500 Market value (DKK): 167,500 Name: Susanna Waters Reason: Closely related to Nicholas Waters, CEO of NeuroSearch Sweden AB Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 18 September 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 2,500 Market value (DKK): 848,750 Name: Nicholas Waters Reason: CEO of NeuroSearch Sweden AB Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 19 September 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 2,500 Market value (kr.): 863,750 Asger Aamund Chairman of the Board Contact person: Anita Milland, Vice President, CFO, telephone: +45 2016 3432 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (in preparation for Phase III), tesofensine in obesity/type 2 diabetes (Phase II), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these
| Source: NTG Nordic Transport Group A/S